Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in resectable malignant pleural mesothelioma
NCT02707666Phase 1Terminated
- Sponsor
- University of Chicago
- Start
- Feb 2016
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in pleural mesothelioma, sponsored by University of Chicago. Primary endpoints: Gamma-Interferon Gene Expression profile response rate at 12 months and Number of participants with adverse events related to pembrolizumab administered prior to surgery at 12 months. Started Feb 2016; status: terminated.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT02707666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707666.